Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta

Statins Get Boost from New Study
Statins should be given to people with high blood pressure or diabetes, even if they don’t have heart disease, according to a study published in the British Medical Journal. While several studies have shown that statins benefit those with cardiovascular disease, this is the first large study which looked at statins as primary prevention in those who were otherwise healthy.
The international team of researchers looked at 10 trials, involving more than 70,000 patients, all of which compared statin therapy with placebo or a control group, and patients were followed for at least four years. They found that statins reduced deaths from all causes by 12 percent and—importantly—reduced the risk of major events such as stroke or heart attack by 30 percentin those without a history of heart disease. These risk reductions are similar to those seen previously in secondary prevention with patients who have established heart disease.
The data suggested that those over 65 with risk factors such as high cholesterol or diabetes were most likely to benefit from long-term statin use, although additional ways of predicting the risk would be useful in identifying those in greatest danger of developing cardiovascular problems. “Given the favourable effects of long term statin treatment, it would be wrong to deny these benefits to people at increased risk for cardiovascular disease,” the authors claimed.
Related articles: